| Trial ID: | L2075 |
| Source ID: | NCT00722631
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Anti-Inflammatory Effects of Pioglitazone
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Impaired Glucose Tolerance|Type 2 Diabetes Mellitus|Atherosclerosis
|
| Interventions: |
DRUG: Pioglitazone|DRUG: Glimepiride
|
| Outcome Measures: |
Primary: Effect of treatment on the nominal change in FDG uptake of atherosclerotic plaque from baseline after 4 months of treatment as measured by FDG-PET/CT imaging., Baseline and 4 months after treatment | Secondary: Change from baseline in plasma glucose/insulin homeostatic parameters and circulating markers of atherosclerosis, Baseline and 4 months and 5 years after treatment|Change from baseline in visceral fat, Baseline and 4 months and 5 years after treatment|All cardiovascular events and all cause death for 5 years, Baseline and 4 months and 5 years after treatment
|
| Sponsor/Collaborators: |
Sponsor: Kurume University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
70
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-05
|
| Completion Date: |
2012-04
|
| Results First Posted: |
|
| Last Update Posted: |
2012-09-27
|
| Locations: |
Kurume University Hospital, Kurume city, 830-0011, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00722631
|
